Document is current
Any future updates will be listed below
-
Authors
Brastianos, Priscilla K. https://orcid.org/0000-0003-4470-8425
Kim, Albert E.
Giobbie-Hurder, Anita https://orcid.org/0000-0003-2496-7737
Lee, Eudocia Quant
Wang, Nancy
Eichler, April F.
Chukwueke, Ugonma
Forst, Deborah A.
Arrillaga-Romany, Isabel C.
Dietrich, Jorg
Corbin, Zachary https://orcid.org/0000-0002-9831-8847
Moliterno, Jennifer
Baehring, Joachim
White, Michael
Lou, Kevin W.
Larson, Juliana
de Sauvage, Magali A.
Evancic, Kathryn
Mora, Joana https://orcid.org/0000-0002-5913-1107
Nayyar, Naema https://orcid.org/0000-0003-3436-8404
Loeffler, Jay
Oh, Kevin
Shih, Helen A.
Curry, William T.
Cahill, Daniel P.
Barker, Fred G.
Gerstner, Elizabeth R.
Santagata, Sandro https://orcid.org/0000-0002-7528-9668
-
Funding
Funding for this research was provided by:
American Brain Tumor Association
Merck, Damon Runyon Cancer Research Foundation, Ben & Catherine Ivy Foundation, American Association of Cancer Research
- License Information
-
More Information
Article History
Received: 18 August 2021
Accepted: 16 February 2022
First Online: 14 March 2022
Change Date: 3 January 2024
Change Type: Update
Change Details: The Supplementary Information file was missing from this article and has now been uploaded. The original article has been corrected.
Competing interests
: PKB has consulted for Tesaro, Angiochem, Genentech-Roche, ElevateBio, Eli Lilly, SK Life Sciences, Advise Connect Inspire (ACI), Pfizer, Voyager Therapeutics, Sintetica, and Dantari, received institutional research funding (to MGH) from Merck, Mirati, Eli Lilly, BMS, and Pfizer, and has received honoraria from Merck, Pfizer, and Genentech-Roche. DAF has Eli Lilly stock ownership. ICA has received institutional research support from Astex Pharmaceuticals and consulted for Boehringer Ingelheim, FORMA Therapeutics, and Agios. DPC has consulted for Lilly, GlaxoSmithKline, Boston Pharmaceuticals, and Iconovir, and serves on the advisory board of Pyramid Biosciences, which includes an equity interest, and has received honoraria and travel reimbursement from Merck for invited lectures, and funding from the US NIH and DOD for clinical trial and grant review. Finally, pembrolizumab is a drug that was developed based in part on scientific research from Dana-Farber Cancer Institute (DFCI), which was licensed to Merck US, the pharmaceutical company that manufactures and sells pembrolizumab. Through the licensing arrangement, DFCI may receive money from this company. Any research that might affect the sales or use of pembrolizumab could change the payments DFCI receives from this company. This is known as an institutional conflict of interest. The remaining authors declare no competing interests.
